Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

News and Views


Nature (10/19/89) Vol. 341, No. 6243, P. 566

The lack of standard reagents, including viruses, makes comparing AIDS research from different laboratories problematic, especially in the case of vaccine research. In Europe, the European Communities have launched the EVA, or European vaccine against AIDS, which will use most of its 2.5 million ECU budget for production and distribution of reagents. The National Institute for Biological Standards and Control in South Mimms, United Kingdom, will monitor quality control, storage, and distribution of the reagents, which will be produced in several laboratories to agreed specifications.


Copyright © 1989 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

Information in this article was accurate in October 19, 1989. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.